TABLE 1.
Summary of baseline demographics of the 18q‐evaluable patients, compared to all patients in the AGITG‐MAX trial and patients not evaluable for copy numbers
| All patients | Excluded patients | 18q evaluable patients | P‐value | |
|---|---|---|---|---|
| (N = 471) | (N = 215) | (N = 256) | ||
| Treatment group | ||||
| C | 156 (33%) | 76 (35%) | 80 (31%) | .38 |
| B + M | 315 (67%) | 139 (65%) | 176 (69%) | |
| ECOG status | ||||
| 0 | 263 (56%) | 114 (53%) | 149 (58%) | .27 |
| 1/2 | 208 (44%) | 101 (47%) | 107 (42%) | |
| Age (years) | ||||
| ≥67 | 244 (52%) | 106 (49%) | 138 (54%) | .35 |
| Prior adjuvant therapy | ||||
| Yes | 123 (26%) | 65 (30%) | 58 (23%) | .07 |
| Side of disease in colon | ||||
| Right | 124 (26%) | 53 (25%) | 71 (28%) | .32 |
| Left | 316 (67%) | 144 (67%) | 172 (67%) | |
| Unknown | 31 (7%) | 18 (8%) | 13 (5%) | |
| Number metastases | ||||
| ≤1 | 272 (58%) | 122 (57%) | 150 (59%) | .71 |
| >1 | 199 (42%) | 93 (43%) | 106 (41%) | |
| Sex | ||||
| Male | 295 (63%) | 132 (61%) | 163 (64%) | .63 |
| Female | 176 (37%) | 83 (39%) | 93 (36%) | |
| Extent of disease at baseline | ||||
| Local involvement | 169 (36%) | 94 (44%) | 75 (29%) | .001 |
| Liver involvement | 353 (75%) | 168 (78%) | 185 (72%) | .17 |
| Lung involvement | 185 (39%) | 80 (37%) | 105 (41%) | .45 |
| Bone involvement | 18 (4%) | 11 (5%) | 7 (3%) | .23 |
| Peritoneal involvement | 84 (18%) | 45 (21%) | 39 (15%) | .12 |
| Other involvement | 49 (10%) | 21 (10%) | 28 (11%) | .76 |
| KRAS | ||||
| Wild type | 224 (71%) | 44 (71%) | 180 (71%) | >.95 |
| Mutant | 90 (29%) | 18 (29%) | 72 (29%) | |
| Not available | 157 | 153 | 4 | |
| BRAF | ||||
| Wild type | 278 (11%) | 55 (89%) | 224 (89%) | >.95 |
| Mutant | 35 (89%) | 7 (11%) | 27 (11%) | |
| Not available | 158 | 153 | 5 |
Note: P‐values were calculated with a χ 2 test. ECOG performance status. 37
Abbreviations: C, capecitabine monotherapy arm; B + M, capecitabine and bevacizumab with or without mitomycin.